Core Viewpoint - The announcement details the stock listing related to the equity incentive plan of Sino Medical Science Technology Co., Ltd., including the number of shares, listing date, and the decision-making process for the stock allocation [2][3][15]. Group 1: Stock Listing Details - The type of stock listing is for equity incentive shares, with a total of 1,904,000 shares to be listed [2]. - The listing date for the shares is set for January 22, 2026 [3][13]. - The shares are part of the 2022 restricted stock incentive plan, with the first allocation of the second vesting period recently completed [3][9]. Group 2: Decision-Making Process - The decision-making process for the stock allocation involved multiple meetings of the board and supervisory board, with independent directors providing clear consent [4][6][8]. - The company conducted a public notice period for the proposed incentive recipients, during which no objections were raised by employees [5][6]. Group 3: Stock Allocation and Impact - A total of 7 individuals will receive the allocated shares [12]. - The new shares will increase the total share capital from 416,048,000 to 417,952,000 shares, representing approximately 0.4576% of the total shares before the allocation [14][15]. - The allocation is not expected to have a significant impact on the company's recent financial status or operating results [15].

Group 1 - The company has approved a proposal to apply for the registration of publicly issued corporate bonds totaling up to RMB 2 billion [1] - The company received approval from the China Securities Regulatory Commission (CSRC) for the public issuance of technology innovation corporate bonds [2] - The company successfully issued the first phase of the corporate bonds with a total scale of RMB 800 million, a subscription multiple of 2.71 times, a term of 3 years, and a coupon rate of 1.98% [2]

Group 1 - The company has approved the use of up to RMB 2.8 billion of idle raised funds and up to RMB 2 billion of idle self-owned funds for cash management, focusing on safe and liquid principal-protected financial products [2] - The cash management authorization is valid from the date of approval at the 2024 annual general meeting until the 2025 annual general meeting [2] - The supervisory board and the sponsor, CITIC Securities Co., Ltd., have expressed their agreement on this matter [2] Group 2 - On December 19, 2025, the company redeemed RMB 450 million of idle raised funds from a fixed deposit at Agricultural Bank of China, earning RMB 337,500 in interest [3] - The principal and interest from the redeemed funds have been returned to the fundraising account, and the company plans to conduct cash management again within the authorized limits [3] - As of the announcement date, the total amount of idle raised funds under cash management that has not yet matured is RMB 1.3 billion, with no overdue amounts reported [4]

Core Viewpoint - The arbitration cases involving Chongqing Xishan Technology Co., Ltd. have been withdrawn, and this decision will not significantly impact the company's daily operations or profits [1][6]. Group 1: Arbitration Case Overview - The company was involved in arbitration initiated by China National Pharmaceutical Group United Medical Devices Co., Ltd. and China National Pharmaceutical Group Beijing United Meidi Medical Devices Co., Ltd. [2] - The arbitration claims amounted to approximately 35.71 million yuan, but the specific compensation obligations and amounts remain unclear [1][2]. Group 2: Arbitration Progress - The Beijing Arbitration Commission accepted the arbitration case on August 29, 2025, under the case number (2025) Jingzhong Anzi No. 07963 [3]. - The arbitration tribunal decided to withdraw the case on January 9, 2026, following the applicant's request to withdraw all arbitration claims [4]. Group 3: Financial Implications - The arbitration fees for the first case totaled 107,956.39 yuan, with the remaining fees refunded to the applicant [4]. - The arbitration fees for the second case amounted to 83,575.2 yuan, with the remaining fees also refunded [6].

Core Viewpoint - The company plans to utilize part of its temporarily idle raised funds for cash management, focusing on high-security and liquid investment products to enhance fund efficiency and maximize shareholder returns [2][3][19]. Investment Overview - **Investment Purpose**: The company aims to maximize shareholder interests by efficiently using temporarily idle raised funds for cash management without affecting the normal investment plans [3]. - **Investment Amount**: The company plans to use no more than RMB 100,000 million (including principal) for cash management [4][13]. - **Funding Source**: As of June 30, 2025, the company has detailed the status of funds raised from its initial public offering in 2019 and subsequent fundraising activities [5][6]. Investment Method - **Investment Products**: The company intends to invest in high-security and liquid products, including but not limited to structured deposits, notice deposits, time deposits, large-denomination certificates of deposit, and income certificates [7][11]. - **Investment Duration**: The investment period is set for 12 months from the date of approval by the board of directors [8][13]. - **Implementation Method**: The board authorizes the management team to handle the purchase of investment products, with the finance department responsible for organizing the implementation [9][13]. Cash Management Returns - **Return Allocation**: The returns from cash management will be prioritized for supplementing any shortfall in investment amounts for projects and for the company's daily operational liquidity, adhering to regulatory requirements [10][19]. Recent Cash Management Situation - The company previously approved the use of up to RMB 130,000 million for cash management, maintaining the same focus on high-security and liquid products [11][12]. Review Procedures - The board of directors approved the cash management proposal on January 19, 2026, ensuring it does not impact the normal operation of investment plans [13][19]. Impact on the Company - The planned use of idle raised funds for cash management will not affect the normal turnover of funds or the operation of investment projects, and it aims to improve fund efficiency and provide better returns for shareholders [17][19].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 二、公司关注并核实情况的说明 经公司董事会确认，公司目前没有任何根据《深圳证券交易所股票上市规则》等有关规定应予以披露而 未披露的事项或与该事项有关的筹划、商谈、意向、协议等；董事会也未获悉公司有根据《深圳证券交 易所股票上市规则》等有关规定应予以披露而未披露的、对公司股票及其衍生品种交易价格产生较大影 响的信息；公司前期披露的信息不存在需要更正、补充之处。 针对公司股票交易异常波动，公司通过电话或函询等方式，对公司控股股东和实际控制人、全体董事及 高级管理人员进行了核实，现就有关核实情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处。 2、公司、控股股东和实际控制人不存在其他关于公司的应披露而未披露的重大事项，或处于筹划阶段 的重大事项。 一、股票交易异常波动的情况介绍 北京直真科技股份有限公司（以下简称"公司"）股票（证券简称：直真科技，证券代码：003007）于 2026年1月15日、1月16日、1月19日连续3个交易日收盘价格跌幅偏离值累计超过 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 1、本期业绩预告适用于净利润为负值的情形。 2、山东惠发食品股份有限公司（以下简称"公司"）2025年年度归属于上市公司股东的净利润预计 为-7,500万元到-6,200万元。公司2025年年度归属于上市公司股东的扣除非经常性损益的净利润预计 为-7,800万元到-6,500万元。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 1、经公司财务部门初步测算，公司2025年年度归属于上市公司股东的净利润预计为-7,500万元到-6,200 万元，较去年同期预计减少4,541.41万元到5,841.41万元，同比下降约273.81%-352.19%。 2、公司2025年年度归属于上市公司股东的扣除非经常性损益的净利润预计为-7,800万元到-6,500万元， 较去年同期预计减少4,468.33万元到5,768.33万元，同比下降约219.93%-283.92%。 （三）本次所预计的业绩未经注册会计师审计 ...

Group 1 - The company expects to turn a profit in 2025, with a focus on strategic transformation and high-quality development [2] - The main reasons for the expected profit include stable revenue growth in the energy-saving business and significant improvements in the management of low-efficiency assets like biomass projects [2] - The performance forecast is based on preliminary calculations by the company's finance department, with final figures to be disclosed in the 2025 annual report [3] Group 2 - The company has communicated with its accounting firm regarding the performance forecast, and there are no disagreements between the two parties [1]

Core Viewpoint - The company has appointed a new signing auditor for the 2025 financial year, ensuring continuity in its auditing process and maintaining compliance with regulatory requirements [1][4]. Group 1: Appointment of Auditor - The company’s board approved the reappointment of Lixin Certified Public Accountants as the financial and internal control auditing firm for the 2025 fiscal year [1]. - The signing auditors originally appointed were Mr. Zhong Jiandong and Mr. Mao Chen, with Mr. Feng Linhao now replacing Mr. Mao due to internal adjustments at the auditing firm [1][2]. Group 2: New Signing Auditor's Background - Mr. Feng Linhao became a certified public accountant in 2024 and has been involved in auditing listed companies since 2018, demonstrating relevant professional competence [2]. - He has no record of violating independence requirements or facing penalties in the last three years, complying with the periodic rotation regulations [3]. Group 3: Impact of Auditor Change - The transition to the new signing auditor has been orderly, and it is expected that this change will not adversely affect the company's financial statements or internal control audit for the 2025 fiscal year [4].

■ 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 湖北江瀚新材料股份有限公司（以下简称"公司"）于近日收到公司董事长甘书官先生，副董事长、总经 理甘俊先生，董事、常务副总经理简永强先生，董事贺有华先生，技术总监阮少阳先生，财务总监侯贤 凤女士，副总经理李云强先生，副总经理汤艳女士（以下简称"承诺人"）《关于自愿承诺12个月内不减 持公司股份的承诺函》，现将相关情况公告如下： 鉴于承诺人所持公司首次公开发行股票前的股份限售期将于2026年1月30日截止。基于对公司价值的认 可和对未来发展的信心，为促进公司持续健康发展、保障全体股东的长远利益，承诺人自愿承诺：自前 述股份限售期满之日起12个月内，即2026年2月2日至2027年2月1日，不以任何方式转让或减持所持有的 公司股份。 截至本公告日，承诺人所持公司股份情况如下： 2026年1月20日 特此公告。 湖北江瀚新材料股份有限公司董事会 ...